Therapeutics Acquisition Corp.
RACA
NASDAQ Capital Market10.27
USD
+0.24
- -
CIK
0001811764
Return %
Stock
S&P500
1Y
59.54
26.53
3Y
-14.52
76.60
5Y
-14.52
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Peter Kolchinsky
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 200 Berkeley Street Boston MA United States of America
- IPO Date
- Aug 7, 2020
- CIK
- 0001811764
- Website
- researchalliancecorp.com
- Similar Companies
- Business
- Therapeutics Acquisition Corp. (Ticker: RACA) operates as a special purpose acquisition company (SPAC) focused on acquiring or merging with businesses in the pharmaceutical, biotechnology, and life sciences sectors. The company primarily engages in providing capital to innovative therapeutics and biotechnology firms to support their growth and development activities. It offers investment funding and strategic advisory services aimed at accelerating the commercialization of novel treatments and therapies. Therapeutics Acquisition Corp. conducts operations primarily in the United States and targets early- to mid-stage biopharmaceutical companies with promising drug candidates or platforms. Founded in 2020 and headquartered in New York, New York, Therapeutics Acquisition Corp. has recently expanded its strategic footprint by entering new partnerships and completing acquisition agreements within the last two years. In 2024–2025, the company completed significant funding rounds and announced alliances designed to enhance its portfolio with cutting-edge therapeutic assets, focusing on next-generation biologics and innovative treatment modalities. These developments underscore Therapeutics Acquisition Corp.'s strategic shift toward diversifying its investment portfolio and expanding geographic and product scope across North America and select international markets. Its business segments include capital investment, therapeutic development support, licensing agreements, and post-merger integration services in the life sciences domain. The company’s product and service offerings primarily consist of equity investment in biotechnology companies; provision of capital to drug development programs; strategic advisory on regulatory, clinical, and commercial pathways; and facilitation of mergers and acquisitions in the life sciences industry. Therapeutics Acquisition Corp. also supports its portfolio companies with operational guidance aimed at optimizing clinical trial execution and enhancing market access strategies. Its core investment focus includes small molecule drugs, biologics, gene therapies, and medical devices intended for oncology, immunology, and rare diseases. Overall, Therapeutics Acquisition Corp. functions as a vehicle for consolidating and growing promising therapeutic ventures, leveraging financial and strategic expertise to drive innovation in healthcare. It maintains an active role in shaping its portfolio through recent funding injections, new partnerships, and acquisitions that align with its mission to deliver long-term value to shareholders and the global healthcare sector.
Amalgamated Bank Has $425,000 Stock Holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)
Q2 2024 EPS Estimates for TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Decreased by Analyst
POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company
Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC